EIM
NBIX icon

Essex Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Essex Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-35,361
Closed -$1.79M – 362
2016
Q3 		$1.79M Buy
35,361
+22,234
+169% +$1.11M 0.29% 91
2016
Q2 		$597K Sell
13,127
-1,319
-9% -$60.7K 0.1% 215
2016
Q1 		$571K Buy
14,446
+1,635
+13% +$64.9K 0.1% 208
2015
Q4 		$725K Sell
12,811
-2,437
-16% -$124K 0.11% 196
2015
Q3 		$607K Buy
+15,248
New +$737K 0.1% 206

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Essex Investment Management's NBIX Position: Q4 2016 in Review

Essex Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 35,361 shares — an estimated $1.79M sold.

Essex Investment Management first reported a position in NBIX in Q3 2015 and held it in 5 quarters. The position peaked at $1.79M in Q3 2016. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Essex Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • Essex Investment Management sold 35,361 Neurocrine Biosciences shares in Q4 2016, an estimated $1.79M.
  • Essex Investment Management first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 5 quarters.
  • Essex Investment Management's Neurocrine Biosciences position peaked at $1.79M in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Essex Investment Management's 13F filing for Q4 2016, filed 8 Feb 2017.